Failed trials for 16 IGF-1R inhibitors and $1.6B later: Time for better preclinical models?
New research published Friday in JAMA Network Open estimates that upwards of $50 billion to $60 billion is spent annually by biopharma companies on failed …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
